Ceftazidime-avibactam + metronidazole + Meropenem
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infection
Conditions
Complicated Intra-abdominal Infection
Trial Timeline
Jan 1, 2013 → Mar 1, 2015
NCT ID
NCT01726023About Ceftazidime-avibactam + metronidazole + Meropenem
Ceftazidime-avibactam + metronidazole + Meropenem is a phase 3 stage product being developed by Pfizer for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01726023. Target conditions include Complicated Intra-abdominal Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01726023 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Intra-abdominal Infection